-
公开(公告)号：WO1991006309A1
公开(公告)日：1991-05-16
申请号：PCT/US1990005993
申请日：1990-10-18
Applicant: VANDERBILT UNIVERSITY
Inventor： VANDERBILT UNIVERSITY , BRIGHAM, Kenneth, L.
IPC: A61K37/22
CPC classification number: A61K48/00 , A61K9/1272
Abstract: A method of expressing a foreign gene in cells of a mammalian organ in vivo includes the step of injecting genetic material capable of inducing desired gene products into a mammal. The genetic material is complexed to cationic liposome carriers. The genetic material is lipofected into cells of the mammalian organ. Gene expression and cellular function of the genetic material are activated to produce the desired foreign products in the cells of the organ.
Abstract translation: 在体内在哺乳动物器官的细胞中表达外源基因的方法包括将能够诱导所需基因产物的遗传物质注入到哺乳动物中的步骤。 遗传物质与阳离子脂质体载体复合。 遗传物质被脂质转染到哺乳动物器官的细胞中。 激活基因表达和遗传物质的细胞功能，以在器官的细胞中产生所需的外来产物。
-
公开(公告)号：WO1998001570A2
公开(公告)日：1998-01-15
申请号：PCT/US1997011667
申请日：1997-07-02
Applicant: VANDERBILT UNIVERSITY , MITCHELL, William M.
Inventor： VANDERBILT UNIVERSITY
IPC: C12N15/59
CPC classification number: C07K14/005 , A61K39/00 , A61K2039/51 , C12N7/00 , C12N2740/15022 , C12N2740/16021 , C12N2740/16122
Abstract: HIV virus mutants having an alteration which inhibits induction of enhancing antibody to said virus are described. Also described are HIV virus mutants in which an antibody-dependent enhancing domain in gp41 includes amino acid alterations. Also described are HIV vaccines comprising HIV gp160 mutants in which an antibody-dependent enhancing domain in gp41 includes at least one amino acid alteration.
Abstract translation: 描述了具有抑制对所述病毒增强抗体诱导的改变的HIV病毒突变体。 还描述了其中gp41中的抗体依赖性增强结构域包括氨基酸改变的HIV病毒突变体。 还描述了包含HIV gp160突变体的HIV疫苗，其中gp41中的抗体依赖性增强结构域包括至少一个氨基酸改变。
-
公开(公告)号：WO1996040769A1
公开(公告)日：1996-12-19
申请号：PCT/US1996009456
申请日：1996-06-05
Applicant: PROGENITOR, INC. , VANDERBILT UNIVERSITY
Inventor： PROGENITOR, INC. , VANDERBILT UNIVERSITY , QUERTERMOUS, Thomas , HOGAN, Bridgid , SNODGRASS, H., Ralph , ZUPANCIC, Thomas, J.
IPC: C07K14/47
CPC classification number: G01N33/5091 , A01K67/0275 , A01K2217/05 , A01K2227/105 , A01K2267/0375 , A61K38/00 , C07K14/475 , G01N33/5008 , G01N33/5011 , G01N33/5064 , G01N33/57484 , G01N2500/00
Abstract: The present invention relates to a member of a novel gene family referred to as developmentally-regulated endothelial cell locus-1(del-1). In particular, the invention relates to del-1 nucleotidesequences, Del-1 amino acid sequences, methods of expressing a functional gene product, and methods of using the gene and gene product. Structurally, members of this gene family contain three EGF-like domains and two discoidin I/factor VIII-like domains. Since del-1 is expressed in endothelial cells and certain cancer cells, it may be useful as an endothelial cell and tumor marker. In addition, the ability of Del-1 to inhibit vascular formation allows its use as an anti-angiogenic agent.
Abstract translation: 本发明涉及称为发育调节内皮细胞基因座-1（del-1）的新型基因家族的成员。 特别地，本发明涉及del-1核苷酸序列，Del-1氨基酸序列，表达功能性基因产物的方法，以及使用该基因和基因产物的方法。 在结构上，该基因家族的成员含有三个EGF样结构域和两个盘状蛋白I /因子VIII样结构域。 由于del-1在内皮细胞和某些癌细胞中表达，所以它可能作为内皮细胞和肿瘤标志物有用。 此外，Del-1抑制血管形成的能力允许其用作抗血管生成剂。
-
24.发明申请CagB AND CagC GENES OF HELICOBACTER PYLORI AND RELATED METHODS AND COMPOSITIONS 审中-公开CagB和CagC基因组及相关方法及组合物
公开(公告)号：WO1996012825A1
公开(公告)日：1996-05-02
申请号：PCT/US1995013659
申请日：1995-10-20
Applicant: VANDERBILT UNIVERSITY
IPC: C12Q01/68
CPC classification number: C07K14/205
Abstract: Isolated CagB gene of H. pylori consisting of nucleotides 193-1158 in the sequence according to Seq. ID. No. 1 and isolated cagC gene of H. pylori with sequence consisting of nucleotides 1170-3830 in the sequence according to Seq. ID. No. 3 are provided, as well as H. pylori specific nucleic acid probes and purified CagB and CagC proteins. CagB and CagC are associated with peptic ulceration and other clinical syndromes in humans infected with H. pylori expressing these antigens. Provided is a method of detecting presence of H. pylori strains expressing CagB or CagC antigens in subject, comprising contacting antibody-containing sample from subject with detectable amounts of CagB or CagC or specific antigenic fragments, detecting binding reaction of CagB or CagC or antigenic fragments and antibody produced by subject. Mutant strains of H. pylori lacking functional CagB or CagC are virulence attenuated due to reduced production of proinflammatory cytokine IL-8.
Abstract translation: 幽门螺杆菌的分离的CagB基因，按照Seq的序列由核苷酸193-1158组成。 ID。 1号和幽门螺杆菌的分离的cagC基因，其序列按照序列Seq的序列由核苷酸1170-3830组成。 ID。 提供了3号，以及幽门螺杆菌特异性核酸探针和纯化的CagB和CagC蛋白。 CagB和CagC与表达这些抗原的幽门螺杆菌感染的人的消化性溃疡和其他临床综合征有关。 本发明提供一种检测受试者中表达CagB或CagC抗原的幽门螺杆菌菌株的存在的方法，其包括使来自受试者的含抗体的样品与可检测量的CagB或CagC或特异抗原片段接触，检测CagB或CagC或抗原片段的结合反应 和受试者产生的抗体。 缺乏功能性CagB或CagC的幽门螺杆菌的突变株由于促炎细胞因子IL-8的产生减少而减毒。
-
25.发明申请COMPOSITIONS FOR AND METHODS OF ENHANCING DELIVERY OF NUCLEIC ACIDS TO CELLS 审中-公开用于增强核酸向细胞递送的组合物和方法
公开(公告)号：WO1995034647A1
公开(公告)日：1995-12-21
申请号：PCT/US1995007543
申请日：1995-06-13
Applicant: VANDERBILT UNIVERSITY
Inventor： VANDERBILT UNIVERSITY , CONARY, Jon, T. , BRIGHAM, Kenneth, L.
IPC: C12N15/00
CPC classification number: C12N15/8206 , A61K47/62 , C12N15/67 , C12N15/8221 , C12N15/87
Abstract: The present invention provides compositions and methods for enhanced delivery of nucleic acids to intracellular compartments. In particular, a method of enhancing delivery and expression of nucleic acids to the nucleus is provided, and a method of enhancing delivery of nucleic acids to the mitochondria is provided, utilizing a nuclear or mitochondrial localization complex, respectively.
Abstract translation: 本发明提供用于增强核酸向细胞内区室递送的组合物和方法。 特别地，提供了增强核酸向核的递送和表达的方法，并且分别利用核或线粒体定位复合物提供增强核酸向线粒体递送的方法。
-
Patent Agency Ranking26.发明申请
公开(公告)号：WO1995025738A1
公开(公告)日：1995-09-28
申请号：PCT/US1995003613
申请日：1995-03-21
Applicant: VANDERBILT UNIVERSITY
Inventor： VANDERBILT UNIVERSITY , THOMPSON, Stuart, A. , BLASER, Martin, J.
IPC: C07H21/04
CPC classification number: C12N9/88 , A61K39/00 , C07K14/205 , C12N9/00 , Y10S435/822
Abstract: An isolated nucleic acid encoding the Helicobacter pylori recombinase comprising the nucleotide sequence defined in the Sequence Listing as SEQ ID NO:1 is provided. Also provided is an isolated nucleic acid that selectively hybridizes with the nucleic acid of claim 1 under stringent conditions and has at least 70 % complementarity with the segment of the nucleic acid of SEQ ID NO:1 to which it hybridizes. Also provided is a mutant strain of H. pylori that does not express a functional recombinase (recA mutant). An immunogenic amount of the recA mutant H. pylori in a pharmaceutically acceptable carrier is provided. A method of immunizing a subject against infection by H. pylori comprises administering to the subject an immunogenic amount of mutant H. pylori in a carrier for the mutant.
Abstract translation: 提供编码幽门螺杆菌重组酶的分离核酸，其包含序列表中定义的核苷酸序列，如SEQ ID NO：1。 还提供了分离的核酸，其在严格条件下选择性地与权利要求1的核酸杂交，并且与其杂交的SEQ ID NO：1的核酸的片段具有至少70％的互补性。 还提供了不表达功能重组酶（recA - 突变体）的幽门螺杆菌突变菌株。 提供了在药学上可接受的载体中的免疫原性量的recA 突变体幽门螺杆菌。 免疫受试者免受幽门螺杆菌感染的方法包括向受试者施用免疫原性量的突变体的载体中的突变型幽门螺杆菌。
-
公开(公告)号：WO1995022988A1
公开(公告)日：1995-08-31
申请号：PCT/US1995002219
申请日：1995-02-23
Applicant: VANDERBILT UNIVERSITY
Inventor： VANDERBILT UNIVERSITY , COVER, Timothy, L. , BLASER, Martin, J.
IPC: A61K39/00
CPC classification number: A61K31/365 , A61K38/00 , A61K39/00 , C07K14/205 , C07K16/121 , G01N2333/205
Abstract: An isolated nucleic acid encoding the Helicobacter pylori vacuolating toxin, consisting of the nucleotides 101 through 3964 of the nucleotide sequence defined in the Sequence Listing as SEQ ID NO: 1 is provided. An isolated nucleic acid from Helicobacter pylori comprising the nucleotide sequence defined in the Sequence Listing as SEQ ID NO: 3 is provided. Isolated nucleic acids that selectively hybridize with the nucleic acids of the invention are provided. Also provided is a genetically altered mutant strain of H. pylori that does not express a functional vacuolating toxin. Purified proteins encoded by the nucleic acids of the invention are provided. A composition comprising an immunogenic amount of a protein or mutant strain of the invention in a pharmaceutically acceptable carrier is provided. A method of immunizing a subject against infection by H. pylori, comprising administering to the subject an immunogenic composition of the invention is provided.
Abstract translation: 提供编码幽门螺杆菌空泡毒素的分离的核酸，其由SEQ ID NO：1的序列表中定义的核苷酸序列的核苷酸101至3964组成。 提供了幽门螺旋杆菌的分离核酸，其包含序列表中定义的核苷酸序列，如SEQ ID NO：3。 提供了与本发明的核酸选择性杂交的分离的核酸。 还提供了不表达功能性空泡毒素的幽门螺杆菌的遗传改变的突变菌株。 提供了由本发明的核酸编码的纯化的蛋白质。 提供了包含免疫原性量的本发明的蛋白质或突变株在药学上可接受的载体中的组合物。 一种免疫受试者免受幽门螺杆菌感染的方法，其包括向受试者施用本发明的免疫原性组合物。
-
公开(公告)号：WO1994014429A1
公开(公告)日：1994-07-07
申请号：PCT/US1993011993
申请日：1993-12-09
Inventor： IOWA STATE UNIVERSITY RESEARCH FOUNDATION INC. , VANDERBILT UNIVERSITY , NISSEN, Steven, L , FLAKKOL, Paul, J. , ABUMRAD, Naji, N.
IPC: A61K31/19
CPC classification number: A61K31/22 , A61K31/19 , A61K31/365
Abstract: Nitrogen retention in human subjects is promoted by administering beta -hydroxy- beta -methylbutyric acid (HMB). The amount of HMB administered is effective to conserve protein as determined by reduction in urinary nitrogen. The method can be used with patients having a negative nitrogen balance due to disease conditions, and also with normal elderly persons who are subject to protein loss. The HMB may be administered orally or by intravenous infusion.
Abstract translation: 通过施用β-羟基-β-甲基丁酸（HMB）促进人受试者的氮保留。 施用的HMB的量对于通过尿氮的还原测定来保存蛋白质是有效的。 该方法可用于疾病条件下具有负氮平衡的患者，也可与正在接受蛋白质损失的正常老年人一起使用。 HMB可以口服或静脉内输注。
-
29.发明申请THE tagA GENE AND METHODS FOR DETECTING PREDISPOSITION TO PEPTIC ULCERATION 审中-公开标签一种用于检测预防性妊娠预后的方法
公开(公告)号：WO1994009023A1
公开(公告)日：1994-04-28
申请号：PCT/US1993009782
申请日：1993-10-13
Applicant: VANDERBILT UNIVERSITY
IPC: C07H21/02
CPC classification number: C12Q1/6883 , A61K38/00 , C07K14/205 , C12Q1/689
Abstract: The present invention provides an isolated nucleic acid encoding an approximately 120-128 kilodalton antigen of Helicobacter pylori, or an antigenic fragment thereof, wherein the antigen is associated with peptic ulceration. The present invention also provides methods of detecting the presence of a Helicobacter pylori strain possessing the 120-128 kilodalton antigen in a subject, comprising the steps of contacting an antibody-containing sample from the subject with a detectable amount of the tagA antigen or antigenic fragment of the present invention and detecting the reaction of the antigen or fragment and the antibody. A mutant H. pylori not expressing a functional tagA antigen is also provided.
Abstract translation: 本发明提供编码幽门螺杆菌约120-128千道尔顿抗原或其抗原性片段的分离的核酸，其中抗原与消化性溃疡有关。 本发明还提供检测受试者中具有120-128千道尔顿抗原的幽门螺杆菌菌株的存在的方法，包括以下步骤：使来自受试者的含抗体的样品与可检测量的标签A抗原或抗原片段 并检测抗原或片段与抗体的反应。 还提供了不表达功能性标记A抗原的突变型幽门螺杆菌。
-
公开(公告)号：WO1992022817A1
公开(公告)日：1992-12-23
申请号：PCT/US1992002368
申请日：1992-03-25
Applicant: VANDERBILT UNIVERSITY
Inventor： VANDERBILT UNIVERSITY , ROBERTS, L., Jackson , OATES, John, A.
IPC: G01N33/536
CPC classification number: G01N33/5308 , G01N33/88
Abstract: The present invention relates to an improved method to diagnose systemic mast cell disorders by detecting the presence or concentration of certain metabolites of prostaglandin D2. In particular, this invention provides a more accurate means to diagnose systemic mast cell disorders than the present standard test involving the detection of Me-histamine.
Abstract translation: 本发明涉及通过检测前列腺素D2的某些代谢物的存在或浓度来诊断系统性肥大细胞疾病的改进方法。 特别地，本发明提供了诊断系统性肥大细胞疾病的更准确的手段，而不是涉及检测Me组胺的本标准试验。
-
-
-
-
-
-
-
-
-
Search Results
64
records
(took 0.033 seconds)
